A randomized, double-blind, placebocontrolled study of bromocriptine in nonfluent aphasia
A randomized, double-blind, placebocontrolled study of bromocriptine in nonfluent aphasia
复制标题
溴隐亭治疗非流利性失语症的随机、双盲、安慰剂对照研究
DOI：
10.1212/wnl.45.12.2272
复制
发表时间：
1995
期刊：
影响因子：
9.9
通讯作者：
S. Starkstein
中科院分区：
文献类型：
--
作者：
L. Sabe;F. Salvarezza;A. García Cuerva;R. Leiguarda;S. Starkstein
我们开展了一项关于溴隐亭治疗非流利性失语的疗效的双盲和安慰剂对照研究。7名患者按随机顺序接受溴隐亭(高达60 mg/d)和相同的安慰剂。终点是指在描述人物的过程中超过3秒的内容词、内容单位和停顿的数量；言语命名；以及言语流畅性。在所检查的任何变量中，溴隐亭与安慰剂相比都没有显著的益处。神经病学1995；45：2272-2274
We carried out a double-blind and placebo-controlled study of the efficacy of bromocriptine in the treatment of nonfluent aphasia. Seven patients received bromocriptine (up to 60 mg/d) and an identical placebo in a randomized order. End points were the number of content words, content units, and pauses more than 3 seconds during the description of a figure; verbal naming; and verbal fluency. There were no significant benefits of bromocriptine over placebo in any of the variables examined. NEUROLOGY 1995;45: 2272-2274